Relatlimab | Interleukin Related interleukin-related.com

Product Name :
Relatlimab

Search keywords :
Relatlimab

drugId :
null

Target Vo:
Lymphocyte activation gene 3 protein

Target Vo Short Name :
LAG3

Moa_Name:
Lymphocyte activation gene 3 protein inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Bristol-Myers Squibb Company

Active Company_Name :
Bristol-Myers Squibb (China) Investment Co Ltd

Active Indication_Name:
Urologic Neoplasms

In Active Indication_Name:
Lymphoma

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FCGR1A Antibody
FGFR1 Oncogene Partner Antibody
HER2 Antibody (YA771): ErbB 2 Antibody (YA771) is a non-conjugated and Mouse origined monoclonal antibody about 138 kDa, targeting to ErbB 2 (1C4). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts